foxo4-dri cancer The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOX04-DRI - Apollo Peptide Sciences
FOX04 DRI Apollo Peptide Sciences Development of a novel senolytic by precise disruption of FOXO4 p53 complex eBioMedicine FOXO4 DRI Peptide 10 mg foxo4 dri peptide senolytic mouse study 2023 2024 Molecular modelling of the FOXO4 TP53 interaction to design peptides for the elimination of senescent cancer cells FOXO4 DRI Peptide for Cellular
Pay in 4 interest-free payments of $6.23 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 2 - Aug 7



